Es gab 50 kürzliche Insider-Transaktionen für Miromatrix Medical Inc. (MIRO), darunter 29 Käufe und 18 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $999.39K und die gesamten Insider-Verkäufe auf $2.08M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Kattungal Laji, Erb John L, Buckman Paul. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — MIRO
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2024-07-16 |
Kattungal Laji |
Vice President of Quality |
Veräußerung |
80,000 |
$3.75 |
$300K |
- |
| 2023-12-13 |
Erb John L |
Director |
Aktienrückgabe |
25,000 |
$3.75 |
$93.75K |
- |
| 2023-12-13 |
Buckman Paul |
Director |
Aktienrückgabe |
25,000 |
$3.75 |
$93.75K |
- |
| 2023-12-13 |
Maag Peter |
Director |
Aktienrückgabe |
58,368 |
- |
- |
- |
| 2023-12-13 |
Burke William P. Mr. |
Director |
Aktienrückgabe |
67,413 |
- |
- |
- |
| 2023-12-13 |
Heine Lisa Wipperman |
Director |
Aktienrückgabe |
67,413 |
- |
- |
- |
| 2023-12-13 |
Ross Jeffrey James |
Chief Executive Officer |
Aktienrückgabe |
100,000 |
$3.26 |
$326K |
- |
| 2023-12-13 |
Douglas James Michael |
Chief Financial Officer |
Aktienrückgabe |
40,000 |
$3.26 |
$130.4K |
- |
| 2023-12-12 |
Erb John L |
Director |
Übernahmeangebot (Verkauf) |
56,260 |
$1.75 |
$98.46K |
54,201 |
| 2023-12-12 |
Buckman Paul |
Director |
Übernahmeangebot (Verkauf) |
52,593 |
$1.75 |
$92.04K |
54,201 |
| 2023-12-12 |
Maag Peter |
Director |
Übernahmeangebot (Verkauf) |
62,092 |
$1.75 |
$108.66K |
58,368 |
| 2023-12-12 |
Burke William P. Mr. |
Director |
Übernahmeangebot (Verkauf) |
66,943 |
$1.75 |
$117.15K |
67,413 |
| 2023-12-12 |
Heine Lisa Wipperman |
Director |
Übernahmeangebot (Verkauf) |
66,943 |
$1.75 |
$117.15K |
67,413 |
| 2023-12-12 |
Ross Jeffrey James |
Chief Executive Officer |
Übernahmeangebot (Verkauf) |
308,775 |
$1.75 |
$540.36K |
87,500 |
| 2023-12-12 |
Douglas James Michael |
Chief Financial Officer |
Übernahmeangebot (Verkauf) |
31,250 |
$1.75 |
$54.69K |
20,000 |
| 2023-12-12 |
United Therapeutics Corp |
10 Percent Owner |
Veräußerung |
- |
- |
- |
27,419,228 |
| 2023-06-01 |
Erb John L |
Director |
RSU-Zuteilung |
54,201 |
- |
- |
110,461 |
| 2023-06-01 |
Buckman Paul |
Director |
RSU-Zuteilung |
54,201 |
- |
- |
106,794 |
| 2023-06-01 |
Maag Peter |
Director |
RSU-Zuteilung |
54,201 |
- |
- |
120,460 |
| 2023-06-01 |
Burke William P. Mr. |
Director |
RSU-Zuteilung |
54,201 |
- |
- |
134,356 |
| 2023-06-01 |
Heine Lisa Wipperman |
Director |
RSU-Zuteilung |
54,201 |
- |
- |
134,356 |
| 2023-03-10 |
Erb John L |
Director |
Informierter Kauf |
31,250 |
$1.60 |
$50K |
56,260 |
| 2023-03-10 |
Buckman Paul |
Director |
Informierter Kauf |
31,250 |
$1.60 |
$50K |
52,593 |
| 2023-03-10 |
Maag Peter |
Director |
Informierter Kauf |
31,250 |
$1.60 |
$50K |
66,259 |
| 2023-03-10 |
Burke William P. Mr. |
Director |
Informierter Kauf |
31,250 |
$1.60 |
$50K |
80,155 |
| 2023-03-10 |
Heine Lisa Wipperman |
Director |
Informierter Kauf |
31,250 |
$1.60 |
$50K |
80,155 |
| 2023-03-10 |
Ross Jeffrey James |
Chief Executive Officer |
Informierter Kauf |
31,250 |
$1.60 |
$50K |
396,276 |
| 2023-03-10 |
Barry John Joseph |
Vice President of R&d |
Informierter Kauf |
6,250 |
$1.60 |
$10K |
35,485 |
| 2023-03-10 |
Douglas James Michael |
Chief Financial Officer |
Informierter Kauf |
31,250 |
$1.60 |
$50K |
51,250 |
| 2023-01-13 |
Ross Jeffrey James |
Chief Executive Officer |
RSU-Zuteilung |
100,000 |
- |
- |
100,000 |
| 2023-01-13 |
Barry John Joseph |
Vice President of R&d |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2023-01-13 |
Douglas James Michael |
Chief Financial Officer |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2022-12-06 |
Ross Jeffrey James |
Chief Executive Officer |
Optionsausübung (Verkauf) |
37,500 |
- |
- |
- |
| 2022-10-01 |
Barry John Joseph |
Vice President of R&d |
RSU-Steuereinbehalt |
765 |
$4.38 |
$3.35K |
19,235 |
| 2022-08-10 |
Erb John L |
Director |
RSU-Zuteilung |
12,788 |
- |
- |
25,010 |
| 2022-08-10 |
Buckman Paul |
Director |
RSU-Zuteilung |
12,788 |
- |
- |
21,343 |
| 2022-08-10 |
Maag Peter |
Director |
RSU-Zuteilung |
12,788 |
- |
- |
35,009 |
| 2022-08-10 |
Burke William P. Mr. |
Director |
RSU-Zuteilung |
12,788 |
- |
- |
48,905 |
| 2022-08-10 |
Heine Lisa Wipperman |
Director |
RSU-Zuteilung |
12,788 |
- |
- |
48,905 |
| 2022-03-15 |
Ross Jeffrey James |
Chief Executive Officer |
Optionsausübung |
35,438 |
$1.25 |
$44.3K |
293,588 |
| 2022-03-01 |
Douglas James Michael |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2022-03-01 |
Douglas James Michael |
Chief Financial Officer |
RSU-Zuteilung |
180,000 |
- |
- |
180,000 |
| 2022-01-13 |
Niebur Brian |
Chief Financial Officer |
RSU-Zuteilung |
20,000 |
$4.20 |
$84K |
20,000 |
| 2022-01-13 |
Kattungal Laji |
Vice President of Quality |
RSU-Zuteilung |
10,000 |
- |
- |
10,000 |
| 2022-01-13 |
Ross Jeffrey James |
Chief Executive Officer |
RSU-Zuteilung |
100,000 |
$4.20 |
$420K |
100,000 |
| 2022-01-13 |
Barry John Joseph |
Vice President of R&d |
RSU-Zuteilung |
20,000 |
$4.20 |
$84K |
20,000 |
| 2022-01-03 |
Niebur Brian |
Chief Financial Officer |
RSU-Zuteilung |
1,500 |
$4.73 |
$7.1K |
1,500 |
| 2022-01-03 |
Burke William P. Mr. |
Director |
Unbekannt |
- |
- |
- |
- |
| 2022-01-03 |
Burke William P. Mr. |
Director |
RSU-Zuteilung |
4,405 |
- |
- |
4,405 |
| 2022-01-03 |
Heine Lisa Wipperman |
Director |
Unbekannt |
- |
- |
- |
- |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall